Pivagabine

Research use only, not for human use.

Pivagabine is a derivative of hydrophobic 4-aminobutyric acid, with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain.

Pivagabine is a derivative of hydrophobic 4-aminobutyric acid, with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain.(In Vivo):Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions.

——

Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions. Animal Model:Adult male Sprague-Dawley CD rats (200-250 g)Dosage:200 mg/kg Administration:i.p.; twice a day for 4 days and 1 hour before killing on the 5th day Result:Prevented the effects of foot-shock stress on CRF concentration in both brain regions. Reduced by 52% the CRF concentration in the hypothalamus but had no effect on that in the cerebral cortex.

CXB-722

Others

Other Targets

Glutamate receptor

——

——

69542-93-4

187.239

C9H17NO3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (267.04 mM)

CC(C)(C)C(=O)NCCCC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years